| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 100.00% | -57.92% | -258.41% | -354.12% | -101.14% | 94.49% |
| Operating Margin | -8256.32% | -7123.13% | -9305.74% | -10337.31% | -8037.60% | -5214.82% | -6817.79% | -4507.61% | -5064.42% | -10534.91% | -8079.50% | -5334.17% |
| EBITDA Margin | -8194.94% | -7063.98% | -9224.18% | -10276.17% | -7911.98% | -5087.49% | -6615.76% | -4280.43% | -4817.58% | -10254.25% | -7958.44% | -5250.36% |
| Net Margin | -7732.04% | -6651.68% | -8492.01% | -10026.94% | -7880.50% | -5275.15% | -6709.74% | -4351.07% | -4928.09% | -10287.75% | -8781.98% | -5112.99% |
| Current Ratio | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 | 21.79 | 2.37 | 4.30 | 2.40 | 5.00 | 8.34 | 6.18 |
| Quick Ratio | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 | 21.79 | 2.37 | 4.30 | 2.40 | 5.00 | 8.34 | 6.18 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -101.02% | -54.77% | -59.42% | -36.40% | -20.15% | -15.06% | -224.50% | -163.24% | -382.82% | -198.32% | -56.41% | -171.57% |
| ROA | -74.09% | -46.74% | -50.76% | -33.31% | -18.92% | -14.33% | -125.43% | -116.15% | -202.74% | -89.20% | -38.45% | -49.57% |
| Asset Turnover | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.04 | 0.01 | 0.00 | 0.01 |
| Book Value / Share | 0.68 | 1.74 | 1.56 | 2.44 | 3.60 | 6.14 | 1.22 | 4.33 | 0.19 | 0.65 | 1.84 | 0.44 |
Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for cancers with significant unmet needs. Its lead candidate, onvansertib, is an oral, selective polo-like kinase 1 (PLK1) inhibitor primarily targeting RAS-mutated metastatic colorectal cancer (mCRC) in combination with standard-of-care chemotherapy and targeted therapies. The company advances clinical programs in this indication via its randomized Phase 2 CRDF-004 trial, evaluating onvansertib in first-line treatment settings. Additional efforts include investigator-initiated trials exploring onvansertib in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer. Cardiff Oncology Inc. operates exclusively in the United States, concentrating on oncology therapeutics that disrupt mitosis in cancer cells. Headquartered in San Diego, California, and founded in 1999, it plays a role in addressing challenging cancer subtypes through innovative targeted treatments.